Immunitybio Osake

Immunitybio Osingo per osake

Osinko per osake yhtiöstä Immunitybio (IBRX) 8.8.2026 päivämäärällä.

Osingo per osake

0,00USD

Viimeksi päivitetty:

Osinko per osake yhtiöstä Immunitybio on 2026 0,00 USD. Osinko per osake yhtiöstä Immunitybio oli 2025 0,00 USD. Se laskee % matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Immunitybio Osakeanalyysi

Mitä Immunitybio tekee? Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Immunitybio osakkeesta

Eurpoolissa voit löytää Osinko per osake Immunitybio:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

Osinko per osake on kokonasinsinko jaettuna ulkona olevilla osakkeilla. Se näyttää, kuinka paljon käteistä jokainen osake saa osinkona.

Osinko per osake:n USD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata Osinko per osake:n Immunitybio historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Osinko — Immunitybio

Kaikki tunnusluvut — Immunitybio